Published in Catheter Cardiovasc Interv on December 19, 2013
Transforming PCI Informed Consent Into an Evidence-based Decision-making Tool (PRISM) | NCT01383382
Chronic total occlusion: To treat or not to treat. World J Cardiol (2014) 0.82
Relationship between the total length of the stents and patients' quality of life after percutaneous coronary intervention. Int J Clin Exp Med (2015) 0.75
Theory and practical based approach to chronic total occlusions. BMC Cardiovasc Disord (2016) 0.75
Chronic total quality of life. Catheter Cardiovasc Interv (2014) 0.75
Effect of angina under-recognition on treatment in outpatients with stable ischaemic heart disease. Eur Heart J Qual Care Clin Outcomes (2016) 0.75
A randomized double-blind placebo-controlled crossover trial of sodium nitrate in patients with stable angina INAS. Future Cardiol (2016) 0.75
Association of β-blocker therapy with long-term clinical outcomes in patients with coronary chronic total occlusion. Medicine (Baltimore) (2016) 0.75
Perceived Cognition after Percutaneous Coronary Intervention: Association with Quality of Life, Mood and Fatigue in the THORESCI Study. Int J Behav Med (2016) 0.75
EuroQol--a new facility for the measurement of health-related quality of life. Health Policy (1990) 59.70
Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med (2009) 17.17
Development and evaluation of the Seattle Angina Questionnaire: a new functional status measure for coronary artery disease. J Am Coll Cardiol (1995) 7.64
Procedural outcomes and long-term survival among patients undergoing percutaneous coronary intervention of a chronic total occlusion in native coronary arteries: a 20-year experience. J Am Coll Cardiol (2001) 2.75
Monitoring the quality of life in patients with coronary artery disease. Am J Cardiol (1994) 2.35
Chronic total occlusion angioplasty in the United States. JACC Cardiovasc Interv (2009) 2.24
Immediate results and one-year clinical outcome after percutaneous coronary interventions in chronic total occlusions: data from a multicenter, prospective, observational study (TOAST-GISE). J Am Coll Cardiol (2003) 2.20
Effectiveness of recanalization of chronic total occlusions: a systematic review and meta-analysis. Am Heart J (2010) 2.18
Percutaneous transluminal coronary angioplasty of chronic total occlusions. Primary success, restenosis, and long-term clinical follow-up. Circulation (1992) 1.89
Impact of complete revascularization with percutaneous coronary intervention on survival in patients with at least one chronic total occlusion. Eur Heart J (2008) 1.85
Percutaneous treatment of chronic total coronary occlusions improves regional hyperemic myocardial blood flow and contractility: insights from quantitative cardiovascular magnetic resonance imaging. JACC Cardiovasc Interv (2008) 1.71
3-year clinical outcome of patients with chronic total occlusion treated with drug-eluting stents. JACC Cardiovasc Interv (2009) 1.60
Percutaneous coronary intervention use in the United States: defining measures of appropriateness. JACC Cardiovasc Interv (2012) 1.54
Changes in myocardial ischemic burden following percutaneous coronary intervention of chronic total occlusions. Catheter Cardiovasc Interv (2011) 1.47
Quantifying the early health status benefits of successful chronic total occlusion recanalization: Results from the FlowCardia's Approach to Chronic Total Occlusion Recanalization (FACTOR) Trial. Circ Cardiovasc Qual Outcomes (2010) 1.20
Contemporary success and complication rates of percutaneous coronary intervention for chronic total coronary occlusions: results from the ALKK quality control registry of 2006. EuroIntervention (2010) 1.18
Evaluation of left ventricular function three years after percutaneous recanalization of chronic total coronary occlusions. Am J Cardiol (2007) 1.18
Coronary angioplasty for chronic total occlusion reduces the need for subsequent coronary bypass surgery. Am Heart J (1990) 1.13
Long-term results of successful and failed angioplasty for chronic total coronary arterial occlusion. Am J Cardiol (1990) 1.07
Improved cardiac survival, freedom from MACE and angina-related quality of life after successful percutaneous recanalization of coronary artery chronic total occlusions. Int J Cardiol (2011) 0.96
Percutaneous angioplasty of chronically occluded coronary arteries: long-term clinical follow-up. Kardiol Pol (2006) 0.90
[Is percutaneous transluminal coronary angioplasty in chronic total coronary occlusion justified? Long term results in a series of 201 patients]. Arch Mal Coeur Vaiss (1995) 0.87
Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation (2005) 43.74
Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med (2007) 25.17
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet (2011) 13.25
Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet (2009) 12.19
Telemonitoring in patients with heart failure. N Engl J Med (2010) 10.82
Sequence variants in SLITRK1 are associated with Tourette's syndrome. Science (2005) 8.20
Effect of PCI on quality of life in patients with stable coronary disease. N Engl J Med (2008) 7.75
Nonvalidation of reported genetic risk factors for acute coronary syndrome in a large-scale replication study. JAMA (2007) 7.12
Trends in survival after in-hospital cardiac arrest. N Engl J Med (2012) 5.67
Hospital quality for acute myocardial infarction: correlation among process measures and relationship with short-term mortality. JAMA (2006) 5.06
Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med (2006) 4.44
Appropriateness of percutaneous coronary intervention. JAMA (2011) 4.33
Reduction in acute myocardial infarction mortality in the United States: risk-standardized mortality rates from 1995-2006. JAMA (2009) 4.24
Serum potassium levels and mortality in acute myocardial infarction. JAMA (2012) 4.09
A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure. Nat Med (2008) 3.98
Recent national trends in readmission rates after heart failure hospitalization. Circ Heart Fail (2009) 3.95
Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina). J Am Coll Cardiol (2013) 3.90
Long-term outcomes in elderly survivors of in-hospital cardiac arrest. N Engl J Med (2013) 3.85
Decision making in advanced heart failure: a scientific statement from the American Heart Association. Circulation (2012) 3.61
Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation (2006) 3.45
Automated external defibrillators and survival after in-hospital cardiac arrest. JAMA (2010) 3.36
Hospital-wide code rates and mortality before and after implementation of a rapid response team. JAMA (2008) 3.30
Hospital variation in time to defibrillation after in-hospital cardiac arrest. Arch Intern Med (2009) 3.27
Contraindicated initiation of β-blocker therapy in patients hospitalized for heart failure. JAMA Intern Med (2013) 3.26
Glucometrics in patients hospitalized with acute myocardial infarction: defining the optimal outcomes-based measure of risk. Circulation (2008) 3.19
Beta2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome. JAMA (2005) 3.16
Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (REACH) study. J Am Coll Cardiol (2002) 3.05
The concept of risk in comparative-effectiveness research. N Engl J Med (2014) 3.04
Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Executive summary. Cardiol Rev (2006) 2.99
Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure. Circulation (2005) 2.85
Effects of exercise training on health status in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA (2009) 2.83
Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials. J Am Coll Cardiol (2005) 2.81
Translational Research Investigating Underlying Disparities in Acute Myocardial Infarction Patients' Health Status (TRIUMPH): design and rationale of a prospective multicenter registry. Circ Cardiovasc Qual Outcomes (2011) 2.77
Racial differences in survival after in-hospital cardiac arrest. JAMA (2009) 2.65
Cardiac performance measure compliance in outpatients: the American College of Cardiology and National Cardiovascular Data Registry's PINNACLE (Practice Innovation And Clinical Excellence) program. J Am Coll Cardiol (2010) 2.62
Concordance of physician ratings with the appropriate use criteria for coronary revascularization. J Am Coll Cardiol (2011) 2.62
Measuring performance for treating heart attacks and heart failure: the case for outcomes measurement. Health Aff (Millwood) (2007) 2.62
Factors associated with racial differences in myocardial infarction outcomes. Ann Intern Med (2009) 2.54
The National Cardiovascular Data Registry (NCDR) Data Quality Brief: the NCDR Data Quality Program in 2012. J Am Coll Cardiol (2012) 2.50
Contemporary mortality risk prediction for percutaneous coronary intervention: results from 588,398 procedures in the National Cardiovascular Data Registry. J Am Coll Cardiol (2010) 2.49
Predictors of quality-of-life benefit after percutaneous coronary intervention. Circulation (2004) 2.45
Relationship between spontaneous and iatrogenic hypoglycemia and mortality in patients hospitalized with acute myocardial infarction. JAMA (2009) 2.42
Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Curr Opin Cardiol (2006) 2.41
All-cause readmission and repeat revascularization after percutaneous coronary intervention in a cohort of medicare patients. J Am Coll Cardiol (2009) 2.40
Health care insurance, financial concerns in accessing care, and delays to hospital presentation in acute myocardial infarction. JAMA (2010) 2.33
Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement: Executive Summary. Crit Pathw Cardiol (2005) 2.31
Diagnostic blood loss from phlebotomy and hospital-acquired anemia during acute myocardial infarction. Arch Intern Med (2011) 2.29
Clinical features and outcomes of carotid artery stenting by clinical expert consensus criteria: a report from the CARE registry. Catheter Cardiovasc Interv (2010) 2.21
Improvement in survival following successful percutaneous coronary intervention of coronary chronic total occlusions: variability by target vessel. JACC Cardiovasc Interv (2008) 2.20
Lack of association between the Trp719Arg polymorphism in kinesin-like protein-6 and coronary artery disease in 19 case-control studies. J Am Coll Cardiol (2010) 2.17
Predictors of smoking cessation after a myocardial infarction: the role of institutional smoking cessation programs in improving success. Arch Intern Med (2008) 2.16
Disease-specific health status as a predictor of mortality in patients with heart failure: a systematic literature review and meta-analysis of prospective cohort studies. Eur J Heart Fail (2014) 2.13
American College of Cardiology and American Heart Association methodology for the selection and creation of performance measures for quantifying the quality of cardiovascular care. Circulation (2005) 2.10
Practice-level variation in warfarin use among outpatients with atrial fibrillation (from the NCDR PINNACLE program). Am J Cardiol (2011) 2.06
Bleeding in patients undergoing percutaneous coronary intervention: the development of a clinical risk algorithm from the National Cardiovascular Data Registry. Circ Cardiovasc Interv (2009) 2.03
Potential impact of optimal implementation of evidence-based heart failure therapies on mortality. Am Heart J (2011) 2.00
Low-output, low-gradient aortic stenosis in patients with depressed left ventricular systolic function: the clinical utility of the dobutamine challenge in the catheterization laboratory. Circulation (2002) 2.00
Health status identifies heart failure outpatients at risk for hospitalization or death. J Am Coll Cardiol (2006) 1.98
The Prospective Registry Evaluating Myocardial Infarction: Events and Recovery (PREMIER)--evaluating the impact of myocardial infarction on patient outcomes. Am Heart J (2006) 1.98
A percutaneous treatment algorithm for crossing coronary chronic total occlusions. JACC Cardiovasc Interv (2012) 1.95
Impact of age and medical comorbidity on the effectiveness of implantable cardioverter-defibrillators for primary prevention. Circ Cardiovasc Qual Outcomes (2009) 1.89
Use of drug-eluting stents as a function of predicted benefit: clinical and economic implications of current practice. Arch Intern Med (2012) 1.89
Identifying patients hospitalized with heart failure at risk for unfavorable future quality of life. Circ Cardiovasc Qual Outcomes (2011) 1.88
Patterns and intensity of medical therapy in patients undergoing percutaneous coronary intervention. JAMA (2011) 1.88
Low levels of high-density lipoprotein cholesterol and increased risk of cardiovascular events in stable ischemic heart disease patients: A post-hoc analysis from the COURAGE Trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation). J Am Coll Cardiol (2013) 1.86
Depressive symptoms are the strongest predictors of short-term declines in health status in patients with heart failure. J Am Coll Cardiol (2003) 1.85
Baseline stress myocardial perfusion imaging results and outcomes in patients with stable ischemic heart disease randomized to optimal medical therapy with or without percutaneous coronary intervention. Am Heart J (2012) 1.84
Omega-6 and trans fatty acids in blood cell membranes: a risk factor for acute coronary syndromes? Am Heart J (2008) 1.83
Patient health status and costs in heart failure: insights from the eplerenone post-acute myocardial infarction heart failure efficacy and survival study (EPHESUS). Circulation (2009) 1.82
The prevalence of and factors associated with chronic atrial fibrillation in Medicare/Medicaid-eligible dialysis patients. Kidney Int (2011) 1.79
Exploring patients' reasons for discontinuance of heart medications. J Cardiovasc Nurs (2009) 1.78
Careers in cardiovascular outcomes research. Circulation (2009) 1.78